Metformin found to act directly on the brain

For over 60 years, doctors have treated type 2 diabetes by focusing on the liver and gut, assuming that is where metformin performs its magic.

However, a scientific paradigm shift has revealed that the brain is a critical, highly sensitive control center for the drug.

Researchers recently discovered that metformin works by interacting with a protein called Rap1, located in a specific brain region known as the ventromedial hypothalamus (VMH).

By switching off this protein and activating specific SF1 neurons, the drug effectively lowers blood sugar.

Remarkably, the brain responds to doses thousands of times lower than what the liver requires.

This discovery suggests that metformin's influence is far more sophisticated than previously thought.

Beyond blood sugar management, scientists are now investigating whether this brain-centered pathway could explain the drug’s potential neuroprotective properties and its ability to slow brain aging.

By targeting these central mechanisms directly, future therapies could potentially achieve better results with lower systemic doses, marking a new era in the treatment of both metabolic and neurodegenerative conditions.